Differentiation syndrome in patients with acute promyelocytic leukemia
- 1 March 2011
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 18 (1), 109-114
- https://doi.org/10.1177/1078155211399163
Abstract
Objective. To review the pathophysiology, risk factors, and management of differentiation syndrome (DS) associated with acute promyelocytic leukemia (APL). Data source. A MEDLINE search was conducted (1977–November 2010) using the terms APL, DS, all- trans retinoic acid (ATRA), retinoic acid syndrome, and arsenic trioxide (ATO). Methods of study selection. English articles identified from the MEDLINE search were evaluated. Data extraction and synthesis. With ATRA, ATO, and chemotherapy, a complete remission is achievable for most newly diagnosed APL patients. However, treatment with the differentiating agents, ATRA and ATO, can lead to the development of DS. Signs and symptoms of this syndrome include hyperleukocytosis and cardiorespiratory compromise. Severe complications can develop, if DS is not recognized early and treated promptly with corticosteroids. In addition, patients with a high white blood cell count at diagnosis may benefit from prophylactic steroids. Conclusions. Early recognition and prompt initiation of corticosteroids are key factors in the management of DS. Healthcare professionals need to be familiar with this complication which can arise from differentiation agents.Keywords
This publication has 24 references indexed in Scilit:
- Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndromeBlood, 2009
- How I treat acute promyelocytic leukemiaBlood, 2009
- Acute Promyelocytic Leukemia — Weapons of Mass DifferentiationThe New England Journal of Medicine, 2009
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2009
- Acute Promyelocytic Leukemia: Recent Advances in Diagnosis and ManagementSeminars in Oncology, 2008
- Retinoic acid syndrome: a reviewJournal of Clinical Pharmacy & Therapeutics, 2008
- Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicinBlood, 2008
- Acute promyelocytic leukemia: from highly fatal to highly curableBlood, 2008
- Retinoic acid syndrome: manifestations, pathogenesis, and treatmentBest Practice & Research Clinical Haematology, 2003
- Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic TrioxideJournal of Clinical Oncology, 2000